Volume 82, Issue 11 (February 2025)
Tehran Univ Med J 2025, 82(11): 864-870 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Faraji N, Alizadeh M, Ghorbani A, Hosami Roodsari H, Akbarpour S, Arefi M. Evaluation of serum amylase levels in hospitalized COVID-19 patients and its association with disease prognosis. Tehran Univ Med J 2025; 82 (11) :864-870
URL: http://tumj.tums.ac.ir/article-1-13409-en.html
URL: http://tumj.tums.ac.ir/article-1-13409-en.html
Neda Faraji *1 
, Mahbobeh Alizadeh2 , Asghar Ghorbani3 , Hadiseh Hosami Roodsari2 , Samane Akbarpour4 , Mohammad Arefi5
, Mahbobeh Alizadeh2 , Asghar Ghorbani3 , Hadiseh Hosami Roodsari2 , Samane Akbarpour4 , Mohammad Arefi5
1- Department of Internal Medicine, Baharlu Hospital, school of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Infectious Diseases, Baharlu Hospital, school of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Pediatrics, Baharlu Hospital, school of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
4- Department of Epidemiology, Baharlu Hospital, school of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
5- Department of Gastroenterology, Baharlu Hospital, school of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Infectious Diseases, Baharlu Hospital, school of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Pediatrics, Baharlu Hospital, school of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
4- Department of Epidemiology, Baharlu Hospital, school of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
5- Department of Gastroenterology, Baharlu Hospital, school of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Abstract: (1377 Views)
Background: This study aimed to evaluate serum amylase levels in hospitalized COVID-19 patients and investigate its association with disease prognosis. Elevated serum amylase levels have been reported in some COVID-19 patients, particularly in severe cases. This increase may indicate pancreatic involvement (pancreatitis) due to viral infection. This cross-sectional study aimed to evaluate the role of serum amylase levels as a prognostic marker in COVID-19 patients.
Methods: This descriptive cross-sectional study was conducted on 150 hospitalized patients with confirmed COVID-19 at Baharloo Hospital, Tehran, over a one-year period (July 2021–July 2022). The results showed that 20% of patients (30 out of 150) had elevated serum amylase levels. Patients with high amylase levels had significantly longer hospital stays (mean 14 days vs. 8 days) and higher mortality rates (15% vs. 5%). Additionally, these patients were more likely to require intensive care (25% vs. 10%). Statistical analysis revealed that elevated serum amylase levels were independently associated with poorer clinical outcomes.
Results: These results have important clinical implications for patient management. Routine measurement of serum amylase at admission could help identify high-risk patients who may benefit from closer monitoring and early intervention. Further research is needed to determine whether specific treatments for pancreatic involvement could improve outcomes in these patients.
Conclusion: These findings suggest that measuring serum amylase levels at admission can serve as a simple and accessible marker for identifying high-risk patients. Elevated amylase in COVID-19 patients is an important biological indicator of multi-organ involvement (pancreas and kidney) and severe inflammation, which is associated with worse prognosis and higher mortality. Monitoring this marker may aid clinical decision-making and improve patient outcomes
Methods: This descriptive cross-sectional study was conducted on 150 hospitalized patients with confirmed COVID-19 at Baharloo Hospital, Tehran, over a one-year period (July 2021–July 2022). The results showed that 20% of patients (30 out of 150) had elevated serum amylase levels. Patients with high amylase levels had significantly longer hospital stays (mean 14 days vs. 8 days) and higher mortality rates (15% vs. 5%). Additionally, these patients were more likely to require intensive care (25% vs. 10%). Statistical analysis revealed that elevated serum amylase levels were independently associated with poorer clinical outcomes.
Results: These results have important clinical implications for patient management. Routine measurement of serum amylase at admission could help identify high-risk patients who may benefit from closer monitoring and early intervention. Further research is needed to determine whether specific treatments for pancreatic involvement could improve outcomes in these patients.
Conclusion: These findings suggest that measuring serum amylase levels at admission can serve as a simple and accessible marker for identifying high-risk patients. Elevated amylase in COVID-19 patients is an important biological indicator of multi-organ involvement (pancreas and kidney) and severe inflammation, which is associated with worse prognosis and higher mortality. Monitoring this marker may aid clinical decision-making and improve patient outcomes
Keywords: COVID-19, disease prognosis, hospitalized patients, intensive care, mortality rate, pancreas, serum amylase.
Type of Study: Original Article |
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
